Search

You searched for "intracameral"

515 results found

Type 3 CNV and anti-VEGF

1 February 2019 | | Retina / Uvea / Vitreous
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...

Does Ozurdex affect perfusion status in vein occlusion?

1 October 2018 | | Cataract and Refractive | intravitreal dexamethasone implant, peripheral nonperfusion, retinal vein occlusion, wide-field fluorescein angiography
Ozurdex (intravitreal dexamethasone implant) has been approved by National Institute of Health & Care Excellence (NICE) for treatment of patients with macular oedema associated with vein occlusion. This study looks at the change in peripheral perfusion status in patients with...

Steroid implants in the treatment of post-epiretinal membrane peel macular oedema

1 February 2018 | | Retina / Uvea / Vitreous | Central retinal thickness, Dexamethasone implant, Fluocinolone acetonide implant, Intravitreal steroid implants, Long-term outcome, Macular pucker surgery, Membrane peeling, Pars plana vitrectomy, Persistent macular edema
This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...

Leber’s hereditary optic neuropathy: from lab to clinic

1 October 2016 | | Neuro-Ophthalmology | Hereditary optic neuropathy, Leber hereditary optic neuropathy, mitochondrial optic neuropathy, optic neuropathy
Leber’s hereditary optic neuropathy (LHON) was the first clinically described mitochondrial disorder (1871). This article reviews the pathophysiology and clinical features of LHON with a focus on translational research. G11778A is currently the most common mutation worldwide and is associated...

Strabismus and ocular motility, demystified

3 April 2024 | | Paediatric Ophthalmology / Strabismus, Optometry
I am a former orthoptist, now trained in medicine and working as a foundation doctor. In my previous work, I was frequently approached by ophthalmology trainees eager for guidance with strabismus and ocular motility. Drawing on my clinical experience, I...

Ranibizumab safety in pregnancy

1 December 2018 | | Retina / Uvea / Vitreous
Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...

2018 update on intravitreal injections

1 December 2018 | | Retina / Uvea / Vitreous | Intravitreal injections, Treatment of retinal diseases, Vitreoretinal diseases
In this review article the authors have highlighted the standardised and structured approach to intravitreal injections (IVI) by examining the recent evidence-based literature. IVI is the most commonly performed procedure worldwide with low potential risk of endophthalmitis. IOP spikes are...

Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO

1 June 2016 | | Paediatric Ophthalmology / Strabismus | Macula, Retina
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...

Intravitreal ranibizumab for the treatment of myopic CNV

1 April 2015 | | Retina / Uvea / Vitreous
The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...

Medical Ophthalmological Society Annual Meeting

14 March 2019
By Muhammad Adil Seelarbokus, Final Year Medical Student, Newcastle University. With an ever-increasing ageing population with multiple co-morbidities presenting to clinics nowadays, the need for medical ophthalmologists is growing. The Medical Ophthalmological Society’s Annual Meeting seemed to be an excellent...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

1 June 2015 | | Retina / Uvea / Vitreous
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

2 December 2019 | | Retina / Uvea / Vitreous, Ophthalmology
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...